Contact this trialFirst, we need to learn more about you.
PLK1 Inhibitor
Onvansertib for Chronic Myelomonocytic Leukemia
Recruiting1 awardPhase 1
Rochester, Minnesota
This trial tests onvansertib, a drug taken by mouth, for patients with chronic myelomonocytic leukemia that has returned or doesn't respond to other treatments. Onvansertib blocks an enzyme needed for cancer cells to grow, aiming to stop their growth and cause them to die.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service